Navigation Links
Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
Date:7/18/2011

nse at the end of treatment and proven or suspected CDAD during the follow-up period were seen in DIFICID-treated and vancomycin-treated patients infected with a BI isolate.

DIFICID should not be used for systemic infections. Only use DIFICID for infection proven or strongly suspected to be caused by C. difficile. The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%).

About Optimer

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has developed and commercialized DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Forward Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation statements related to Optimer's plans to commercialize DIFICID, including with its co-promotion partner, the incidence of CDAD, the ability of Optimer's Patient Assistance Program to expand access to DIFICID, and Optimer's expectations regarding the impact of the commercial launch of DIFICID. Words such as "believes", "would", "anticipates", "plans", "expects", "may", "intend", "will", and similar expressions are intended to identify forward-lookin
'/>"/>

SOURCE Optimer
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
3. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
4. Optimer Pharmaceuticals Expands Senior Management Team
5. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
6. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
7. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
8. Trading Halted Today in Optimer Pharmaceuticals Stock
9. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
10. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
11. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 1, 2015 CEFALY Technology , ... stimulation device specifically authorized for use prior to the ... a new PET trial showing that the Cefaly device ... brain in migraine patients, namely the orbitofrontal cortex and ... scan, which is an imaging test of the brain, used a radioactive ...
(Date:6/1/2015)... SETAUKET, N.Y. , June 1, 2015 /PRNewswire/ ... (NASDAQ: HRTX ) today announced positive, top-line ... study.  MAGIC evaluated the efficacy and safety of ... candidate SUSTOL ® (granisetron injection, extended release) ... intravenous (IV) neurokinin-1 (NK 1 ) receptor antagonist ...
(Date:6/1/2015)... 2015   OTC Markets Group Inc. ... financial marketplaces for 10,000 U.S. and global securities, ... Diego -based biopharmaceutical company, on its NASDAQ ... public venture market for entrepreneurial and development stage ... "We,re happy to congratulate OncoSec ...
Breaking Medicine Technology:New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2New cancer therapy study results - MAGIC Trial 2OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2
... and drug withdrawal, CHICAGO, May 15, 2007 /PRNewswire/ ... and physicians commissioned by the National,Headache Foundation and ... migraine patients are currently taking potentially,addictive medications that ... by the U.S. Food and Drug Administration for ...
... , LONDON, UK and ATLANTA, US, May 14, ... Inc. (NASDAQ:SCRX) today,announce the successful completion of the ... a calcium ,channel blocking agent for the treatment ... the new Sular formulation is,bioequivalent to Sciele's currently ...
Cached Medicine Technology:Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 2Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 3Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 5Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 6SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme 2SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme 3
(Date:6/2/2015)... 02, 2015 The Radiosurgery Society® ... from the RSSearch® Patient Registry evaluating the treatment ... (SBRT) for the treatment of centrally located primary ... , The study, published in the May, ... included 111 patients with 114 centrally located lung ...
(Date:6/2/2015)... Colorado (PRWEB) June 02, 2015 ... Chief Medical Officer at the Steadman Philippon Research Institute, ... Too Early for Single Sport Specialization? ” This was ... Sports Medicine (AOSSM) Research Committee that was recently published ... data for this project was limited, there is evidence ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Each year, ... Insiders’ Choice Beauty Awards. This year, the organization’s members ... the winner of the QVC® Beauty Quest Award at ... results-driven Micro Emulsion (ME) Technology and 2-in-1 approach to ... Also noting the brand’s loyal consumer and professional fan ...
(Date:6/2/2015)... View, CA (PRWEB) June 02, 2015 ... mandated vaccination schedule for children to attend public or ... Judiciary and Education but bypassed the Appropriations Committee (Sacramento ... floor 25-10 despite contentious hearings. , “We believe ... Personal Belief Exemptions (PBEs) more than it will (the) ...
(Date:6/1/2015)... June 02, 2015 The National ... Wirski as a 2015-2016 inductee into its VIP ... this prestigious distinction for leadership in business. NAPW is ... boasting more than 700,000 members and over 200 operating ... this prestigious honor,” said NAPW President Star Jones. “Job ...
Breaking Medicine News(10 mins):Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 2Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 3Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 2Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 3Health News:Scalisi Skincare Wins Coveted CEW QVC Beauty Quest Award for Innovative and Patented Formulation 2Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2Health News:National Association of Professional Women Inducts Miriam Wirski, Holistic Life Coach, Into its VIP Woman of the Year Circle 2
... Data that shed new light on,the treatment of ... immune thrombocytopenic purpura, and venous,thrombosis in relation to ... 49th Annual Meeting of the American Society of,Hematology ... this new research,on Saturday, December 8, from 10:00 ...
... is a clear link between GABA a chemical ... in the brain and nicotine dependence, according ... of Neuropsychopharmacology (ACNP) annual meeting. Researchers discovered that nicotine ... could potentially help curb the pleasurable effects of nicotine ...
... link between mitochondria, memory and socialization , FRIDAY, ... respiration deficiencies in mitochondria (the source of energy ... behavior and spatial memory, Japanese researchers report. , ... link between mitochondrial malfunction and mental illness in ...
... more invasive treatment is necessary, researchers say , , FRIDAY, Dec. 7 ... test to detect lung cancer, according to a Duke University Medical ... Dec. 10 issue of the Journal of Clinical Oncology , ... RBP, SCC and AAT -- may provide a simple follow-up for ...
... that we must remain vigilant,in protecting women,s access to ... care professionals who provide that care, WASHINGTON, Dec. ... President and CEO of the National Abortion,Federation, on the ... Albuquerque,NM:, As the professional association of abortion providers, ...
... KING OF PRUSSIA, Pa., Dec. 7 Universal ... that its Board of Directors,authorized an additional 5 ... shares remaining under previously announced authorizations.,Pursuant to the ... time as,conditions allow, may purchase shares on the ...
Cached Medicine News:Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 2Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 3Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 4Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 5Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 6Health News:Study suggests nicotine addiction might be controlled by influencing brain mechanisms 2Health News:Blood Test to Detect Lung Cancer Being Eyed 2
... Savant offers several different two-stage, oil-sealed, rotary ... freeze drying applications. Each pump comes complete ... Kit) and and Oil Mist Filter (EMF-10). ... full gas ballast to keep the oil ...
Produces vacuum pressures required for 96 well kits...
Inquire...
... The Perfect Single Vac ... one 96-well plate in 30 ... with an "open/closed" switch and ... for easy operation. contains vacuum ...
Medicine Products: